Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease

Journal of Neuroscience

Volumn 31, Issue 48, 2011, Pages 17649-17658

  Pickrell, Alicia M ^a   Pinto, Milena ^a   Hida, Aline ^a   Moraes, Carlos T ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPAMINE; 3, 4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; BENSERAZIDE; CARBIDOPA; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; LEVODOPA; NORADRENALIN; PSTI RESTRICTION ENDONUCLEASE; RESTRICTION ENDONUCLEASE; SEROTONIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXPERIMENTAL TEST; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MITOCHONDRIAL DNA DEPLETION; MOTOR ACTIVITY; MOUSE; NONHUMAN; PARKINSON DISEASE; POLE TEST; PRIORITY JOURNAL; ROTAROD TEST; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; WEIGHT GAIN; WESTERN BLOTTING;

ANIMALS; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA, MITOCHONDRIAL; DOPAMINE; MICE; MICE, TRANSGENIC; NEURONS; PARKINSON DISEASE;

EID: 82555174637     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4871-11.2011     Document Type: Article

References (36)

1. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG (1981) Sequence and organization of the human mitochondrial genome. Nature 290:457-465.
2. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38:515-517.
3. Besson MJ, Cheramy A, Feltz P, Glowinski J (1969) Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. Proc Natl Acad Sci U S A 62:741-748.
4. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
5. Cagniard B, Beeler JA, Britt JP, McGehee DS, Marinelli M, Zhuang X (2006) Dopamine scales performance in the absence of new learning. Neuron 51:541-547.
6. Díaz Castro B, García-Flores GP, Pintado O, Rodríguez-Gòmez JA, Lòpez-Bareno J, Piruat JI (2010) Early postnatal catecholaminergic neural loss in a mouse model genetically deficient in mitochondrial complex II. Soc Neurosci Abstr 36:52.13.
7. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, Hoffer B, Cullheim S, Mohammed AH, Olson L, Larsson NG (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 104:1325-1330.
8. Fukui H, Moraes CT (2009) Mechanisms of formation and accumulation of mitochondrial DNA deletions in aging neurons. Hum Mol Genet 18:1028-1036.
9. German DC, Manaye KF, White CL 3rd, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, Mann DM (1992) Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32:667-676.
10. Goedert M, Jakes R, Anthony Crowther R, Grazia Spillantini M (2001) Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy as α-synucleinopathies. Methods Mol Med 62:33-59.
11. Good CH, Hoffman AF, Hoffer BJ, Chefer VI, Shippenberg TS, Bäckman CM, Larsson NG, Olson L, Gellhaar S, Galter D, Lupica CR (2011) Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J 25:1333-1344.
12. Greene JG, Dingledine R, Greenamyre JT (2005) Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis 18:19-31.
13. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, Hilker R (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132:3285-3297.
14. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38:518-520.
15. Magen I, Chesselet MF (2010) Genetic mouse models of Parkinson's disease: the state of the art. Prog Brain Res 184:53-87.
16. Marien M, Briley M, Colpaert F (1993) Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol 236:487-489.
17. Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73:45-48.
18. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC (1991) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41:507-523.
19. Meredith GE, Kang UJ (2006) Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 21:1595-1606.
20. Navailles S, De Deurwaerdére P (2011) Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl) 213:213-242.
21. Papka M, Rubio A, Schiffer RB (1998) A review of Lewy body disease, an emerging concept of cortical dementia. J Neuropsychiatry Clin Neurosci 10:267-279.
22. Pickrell AM, Fukui H, Wang X, Pinto M, Moraes CT (2011) The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. J Neurosci 31:9895-9904.
23. Reeve AK, Krishnan KJ, Elson JL, Morris CM, Bender A, Lightowlers RN, Turnbull DM (2008) Nature of mitochondrial DNA deletions in substantia nigra neurons. Am J Hum Genet 82:228-235.
24. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827.
25. Schapira AHV, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ 1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55:2142-2145.
26. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3:1101-1108.
27. Shimohama S, Sawada H, Kitamura Y, Taniguchi T (2003) Disease model: Parkinson's disease. Trends Mol Med 9:360-365.
28. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550.
29. Song DD, Haber SN (2000) Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 20:5102-5114.
30. Srivastava S, Moraes CT (2001) Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. HumMol Genet 10:3093-3099.
31. Srivastava S, Moraes CT (2005) Double-strand breaks of mouse muscle mtDNA promote large deletions similar to multiple mtDNA deletions in humans. Hum Mol Genet 14:893-902.
32. Vyas I, Heikkila RE, Nicklas WJ (1986) Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 46:1501-1507.
33. Wenz T, Diaz F, Spiegelman BM, Moraes CT (2008) Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 8:249-256.
34. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT (2009) Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A 106:20405-20410.
35. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, et al. (2010) PGC-1, a potential therapeutic target for early intervention in Parkinson's disease. Sci TranslMed 2:52-73.
36. Zhou Q-Y, Palmiter RD (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83:1197-1209.